National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 17 of 41
Tetravalent Chimeric Dengue Vaccine Trial
NCT01110551
High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
NCT00885703
A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis
NCT01122914
Blood and Plasma Collection For Use in Future Clinical Trials
NCT01136057
Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine
NCT01084291
Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
NCT01111305
Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology
NCT01089114
Empiric Therapy of Mucopurulent Cervicitis (MPC)
NCT01072136
An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...
NCT01086657
Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally
NCT00914732
Safety and Immune Response to an Investigational Dengue Type 2 Vaccine
NCT01073306
Evaluating the Safety of and Immune Response to an HIV Vaccine Followed by Booster, Administered by Two Devices, in HIV-Uninfected Adults
NCT01260727
Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System
NCT01063309
Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins
NCT01054872
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
NCT00991289
Alloantibodies in Pediatric Heart Transplantation
NCT01005316
Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers
NCT00992069
Treatment Failure of Chlamydial Infection in Males and Females in Youth Correctional Facilities
NCT00980148
Evaluation of the Cellular Pharmacology of Tenofovir and Emtricitabine According to HIV Infection Status
NCT01040091
Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
NCT00950248
Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents
NCT00921557
H1N1 Vaccine at Two Dose Levels in HIV Positive Adults
NCT00992433
Novartis H1N1 Vaccine in Pregnant Women
NCT00992719
Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children
NCT01021397
Safety of and Immune Response to the PENNVAX-B DNA Vaccine With and Without IL-12 in HIV-uninfected Adults
NCT00991354
VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years
NCT00995982
Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women
NCT00992017
Live Kidney Donor Study - Cross-Sectional and Historical Cohort Study
NCT00951977
Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth
NCT00992836
Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma
NCT00978120
Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)
NCT01031537
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults
NCT00831012
Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations
NCT00963157
A Pilot Study for Collection of Anti-Influenza A Immune Plasma
NCT00984451
Live Kidney Donor Study -Renal Function Study
NCT01158742
H1N1 Vaccine in Pregnant Women
NCT00963430
Studies in the Pathogenesis of Systemic Capillary Leak Syndrome
NCT00936325
VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old
NCT00973895
Sanofi Pasteur, TIV + H1N1, Pediatric Population
NCT00943202
CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
NCT00943488
Sanofi H1N1 + TIV - Adults and Elderly
NCT00943878
Peds Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels
NCT00944073
Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents
NCT00766597
Nontypeable H. Influenzae in Healthy Adults
NCT00905385
Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
NCT00943631
Longitudinal Study of the Human Intestinal Microbiome
NCT00832286
Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus
NCT00919178
Immune Development in Pediatric Transplantation (IMPACT)
NCT00951353
Early Immune Responses to Vaccination - A Substudy to HVTN 205
NCT00908323
Pathogenesis of Physical Induced Urticarial Syndromes
NCT00887939
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.